New Zealand markets closed

Eli Lilly and Company (LLY)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
762.66+8.49 (+1.13%)
At close: 04:00PM EDT
765.00 +2.34 (+0.31%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close754.17
Open762.28
Bid0.00 x 800
Ask0.00 x 1000
Day's range758.25 - 769.68
52-week range323.26 - 800.78
Volume2,489,042
Avg. volume3,213,986
Market cap724.652B
Beta (5Y monthly)0.34
PE ratio (TTM)131.49
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield5.20 (0.68%)
Ex-dividend date14 Feb 2024
1y target estN/A
  • Insider Monkey

    20 Most Overweight States in the US

    In this article, we will be taking a look at the 20 most overweight states in the US. If you do not wish to learn about the global obesity market, head straight to the 5 Most Overweight States in the US. In the United States, the issue of obesity remains a significant public health concern, […]

  • Insider Monkey

    20 Most Owned Stocks by Hedge Funds Now

    In this article, we will be taking a look at the 20 most owned stocks by hedge funds now. To skip our detailed analysis of the current stock market news, you can go directly to see the 5 Most Owned Stocks by Hedge Funds Now. Rate Cuts in June As the US economy continues to […]

  • Barrons.com

    Wegovy and Zepbound Cast Shadow Over Madrigal’s Liver Drug

    The Food and Drug Administration’s approval of a liver drug from Madrigal Pharmaceuticals marks a turning point in the often-agonizing campaign to get a treatment onto the market for the condition known as MASH. It is also a reminder for investors that biopharma is opening other large markets aside from weight loss. For many investors, the whole story in biopharma these past 18 months has been the new obesity and Type 2 diabetes drugs from Eli Lilly and Novo Nordisk known as Zepbound and Wegovy.